Difelikefalin
- TRADE NAME: Korsuva (Cara Therapeutics)
- INDICATIONS:
Treatment of pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
- CLASS: Opioid agonist, Opioid kappa receptor agonist
- HALF-LIFE: 23–31 hours (in hemodialysis patients prior to dialysis)
FDA APPROVAL DATE: 08/23/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:No clinical studies evaluating the drug interaction potential of difelikefalin were conducted.
Insufficient data in pregnant women to evaluate a drug-associated risk for major birth defects or miscarriage.
Dizziness, somnolence, and mental status changes have occurred in patients taking difelikefalin. Difelikefalin may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. Advise patients not to drive or operate dangerous machinery until the effect of difelikefalin on a patient’s ability to drive or operate machinery is known.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric